Holen Sie sich die Stockscreener-App
10.31
0.98%
0.10
Handel nachbörslich:
10.39
0.08
+0.78%
Schlusskurs vom Vortag:
$10.21
Offen:
$10.34
24-Stunden-Volumen:
1.72M
Relative Volume:
1.43
Marktkapitalisierung:
$1.10B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-249.31M
KGV:
-3.5923
EPS:
-2.87
Netto-Cashflow:
$-209.70M
1W Leistung:
-7.45%
1M Leistung:
-13.51%
6M Leistung:
-56.30%
1J Leistung:
-62.22%
1-Tages-Spanne:
$10.14
$10.61
1-Wochen-Bereich:
$10.12
$11.24
52-Wochen-Spanne:
$10.12
$31.47
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Firmenname
Rocket Pharmaceuticals Inc
Sektor
Branche
Telefon
646-440-9100
Adresse
350 FIFTH AVENUE, NEW YORK, NY
Vergleichen Sie RCKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
10.31 | 1.10B | 0 | -249.31M | -209.70M | -2.87 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | Wedbush | Outperform |
| 2024-12-18 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-01 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-11-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-11-01 | Eingeleitet | BTIG Research | Buy |
| 2022-07-08 | Eingeleitet | Raymond James | Outperform |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2021-02-18 | Eingeleitet | Needham | Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-12-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-07-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2019-11-06 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-26 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-04-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-03-15 | Eingeleitet | BofA/Merrill | Buy |
| 2019-02-05 | Eingeleitet | Oppenheimer | Outperform |
| 2018-09-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-07-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Rocket Pharmaceuticals Inc Aktie (RCKT) Neueste Nachrichten
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 12-Month Low – Time to Sell? - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Down 4%Here's Why - MarketBeat
How to Take Advantage of moves in (RCKT) - Stock Traders Daily
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 52-Week LowHere's Why - MarketBeat
Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Mirador Capital Partners LP - MarketBeat
JPMorgan Chase & Co. Decreases Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Hits New 12-Month LowHere's What Happened - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Up 6.9%Time to Buy? - MarketBeat
Learn to Evaluate (RCKT) using the Charts - Stock Traders Daily
RCKTRocket Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Q4 Earnings Estimate for RCKT Issued By Wedbush - Defense World
Brokers Set Expectations for RCKT Q4 Earnings - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading 3.7% HigherWhat's Next? - MarketBeat
Wedbush starts Rocket Pharmaceuticals with Outperform into ‘inflection year’ - Yahoo Finance
Rocket Pharmaceuticals (NASDAQ:RCKT) Now Covered by Analysts at Wedbush - Defense World
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock poised for growth - Investing.com Canada
Rocket Pharmaceuticals (NASDAQ:RCKT) Now Covered by Wedbush - MarketBeat
Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
(RCKT) On The My Stocks Page - Stock Traders Daily
Geode Capital Management LLC Boosts Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Position Decreased by HighTower Advisors LLC - Defense World
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy' - MSN
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 1-Year LowHere's Why - MarketBeat
State Street Corp Buys 322,156 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Franklin Resources Inc. Cuts Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
State Street Corp Has $57.29 Million Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap UpShould You Buy? - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Now Covered by Jefferies Financial Group - MarketBeat
Head-To-Head Review: InMed Pharmaceuticals (NASDAQ:INM) & Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
RTW INVESTMENTS, LP Increases Stake in Rocket Pharmaceuticals Inc - GuruFocus.com
(RCKT) Trading Report - Stock Traders Daily
Synovus Financial Corp Decreases Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Leerink Partnrs Has Positive Outlook of RCKT FY2024 Earnings - MarketBeat
FY2024 Earnings Estimate for RCKT Issued By Leerink Partnrs - Defense World
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com Australia
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals (NASDAQ:RCKT) Hits New 1-Year LowHere's What Happened - MarketBeat
Rocket Pharmaceuticals completes $178.1 million offering - Investing.com India
Rocket Pharma Stock Slips Despite New Long-Term Data On Phase-I Study; Retail Sentiment Slides - MSN
Rocket Pharmaceuticals completes $178.1 million offering By Investing.com - Investing.com Australia
RSI Alert: Rocket Pharmaceuticals (RCKT) Now Oversold - Nasdaq
RCKT Stock Hits 52-Week Low at $12.62 Amid Market Challenges - Investing.com India
RCKT Stock Hits 52-Week Low at $12.62 Amid Market Challenges By Investing.com - Investing.com South Africa
Finanzdaten der Rocket Pharmaceuticals Inc-Aktie (RCKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rocket Pharmaceuticals Inc-Aktie (RCKT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Patel Kinnari | See Remarks |
Nov 21 '24 |
Sale |
13.05 |
4,588 |
59,892 |
392,395 |
| Shah Gaurav | CEO |
Nov 21 '24 |
Sale |
13.05 |
11,091 |
144,782 |
707,328 |
| Wilson Martin | General Counsel |
Nov 21 '24 |
Sale |
13.05 |
1,175 |
15,338 |
63,560 |
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):